Endothelin News and Research RSS Feed - Endothelin News and Research

Endothelins are proteins that constrict blood vessels and raise blood pressure. They are normally kept in balance by other mechanisms, but when they are over-expressed, they contribute to high blood pressure (hypertension) and heart disease.
New blood biomarkers could lead to better evaluation of treatment for patients with PAH

New blood biomarkers could lead to better evaluation of treatment for patients with PAH

New blood biomarkers reflecting vasoreactivity in lung blood vessels of patients with heart- and lung disease, can lead to simplified diagnostics and better evaluation of treatment for patients with the condition pulmonary arterial hypertension (PAH). [More]
14th APS symposium highlights role of endothelin in many biological functions

14th APS symposium highlights role of endothelin in many biological functions

Endothelin (ET) is a peptide produced by cells in the blood vessels and has powerful vessel-constricting effects. Although endothelin is mainly associated with its role in blood pressure control and cardiovascular diseases, it continues to appear in other physiological functions and diseases. [More]
Endothelin system offers potential therapeutic target for ALS

Endothelin system offers potential therapeutic target for ALS

Amyotrophic lateral sclerosis (ALS) is a disorder in which cells of the nervous system die, leading to muscle weakness that impacts breathing, movement and other physical functions. [More]
Study provides mechanism for EDNRB gene's role in adaptation to life at high altitudes

Study provides mechanism for EDNRB gene's role in adaptation to life at high altitudes

Ethiopians have lived at high altitudes for thousands of years, providing a natural experiment for studying human adaptations to low oxygen, a condition known as hypoxia. One factor that may enable Ethiopians to tolerate high altitudes and hypoxia is the endothelin receptor type B (EDNRB) gene. [More]
Updated guidelines released for treatment of idiopathic pulmonary fibrosis

Updated guidelines released for treatment of idiopathic pulmonary fibrosis

Updated guidelines on the treatment of idiopathic pulmonary fibrosis (IPF) have been released by an international group of leading respiratory societies, The new guidelines, issued by the American Thoracic Society, the European Respiratory Society, the Japanese Respiratory Society, and the Latin American Thoracic Association, were published in the American Thoracic Society's American Journal of Respiratory and Critical Care Medicine. [More]
Stopping cocaine use may lower levels of ET-1 protein that plays key role in coronary artery disease

Stopping cocaine use may lower levels of ET-1 protein that plays key role in coronary artery disease

For people who use cocaine, stopping or reducing cocaine use is associated with decreased levels of endothelin-1 (ET-1)--a protein that plays a key role in the development of coronary artery disease, reports a study in the Journal of Addiction Medicine, the official journal of the American Society of Addiction Medicine. [More]
PAH diagnosis delayed for adult congenital heart disease patients

PAH diagnosis delayed for adult congenital heart disease patients

Pulmonary arterial hypertension is often not diagnosed in adult patients with congenital heart disease until 6 years or more after their symptoms first appear, research shows. [More]
Researchers call for earlier PAH diagnosis and treatment

Researchers call for earlier PAH diagnosis and treatment

A study has found that treatment of pulmonary arterial hypertension in patients younger than 55 years significantly improves their performance on the 6-minute walk test. [More]
Early decline in 6MWT distance predicts PAH worsening

Early decline in 6MWT distance predicts PAH worsening

Research shows that an early decline in 6-minute walk test distance can predict worsening of disease in patients with pulmonary arterial hypertension. [More]
Selten Pharma's SPI-026 granted FDA Orphan Drug Designation for treatment of PAH

Selten Pharma's SPI-026 granted FDA Orphan Drug Designation for treatment of PAH

Selten Pharma, Inc., a privatively held biopharmaceutical company focused on the development and commercialization of therapies for the treatment of rare diseases, announced today that its lead compound tacrolimus (SPI-026) has been granted Orphan Drug Designation by the U.S. Food & Drug Administration for the treatment of pulmonary arterial hypertension (PAH). [More]
UT Southwestern neuroscientists identify key brain cells that control circadian rhythms

UT Southwestern neuroscientists identify key brain cells that control circadian rhythms

UT Southwestern Medical Center neuroscientists have identified key cells within the brain that are critical for determining circadian rhythms, the 24-hour processes that control sleep and wake cycles, as well as other important body functions such as hormone production, metabolism, and blood pressure. [More]
Endothelin gene expression linked to vision loss in premature babies

Endothelin gene expression linked to vision loss in premature babies

A gene known to play a major role in constricting blood vessels also appears to be a major player in the aberrant blood vessel growth that can destroy the vision of premature babies. [More]
Vascular receptor autoantibodies implicated in SSc-PAH

Vascular receptor autoantibodies implicated in SSc-PAH

medwireNews: Autoantibodies to endothelin receptor type A and angiotensin receptor type-1 predict the development of, and mortality from, systemic sclerosis-associated pulmonary arterial hypertension, research suggests. [More]
Targeted treatments may improve idiopathic PAH survival

Targeted treatments may improve idiopathic PAH survival

Patients with idiopathic pulmonary arterial hypertension may live longer if they are given targeted treatments than if they receive conventional management, researchers suggest. [More]
CHEST guideline released for PAH

CHEST guideline released for PAH

An updated CHEST guideline for treating pulmonary arterial hypertension provides some evidence-based recommendations but also highlights many evidence gaps. [More]
Olive oil supplements may counteract adverse cardiovascular effects of exposure to air pollution

Olive oil supplements may counteract adverse cardiovascular effects of exposure to air pollution

Taking olive oil supplements may counteract some of the adverse cardiovascular effects of exposure to air pollution, according to a new study presented at the 2014 American Thoracic Society International Conference. [More]
Olive oil supplements may counteract adverse cardiovascular effects of air pollution

Olive oil supplements may counteract adverse cardiovascular effects of air pollution

Taking olive oil supplements may counteract some of the adverse cardiovascular effects of exposure to air pollution, according to a new study presented at the 2014 American Thoracic Society International Conference. [More]
Ambrisentan cleared for use with phenprocoumon

Ambrisentan cleared for use with phenprocoumon

Starting treatment with ambrisentan does not necessitate adjusting the dose of the oral anticoagulant phenprocoumon in patients with pulmonary hypertension who require both medications, report researchers. [More]
Meta-analysis links signalling pathways to bipolar disorder

Meta-analysis links signalling pathways to bipolar disorder

A meta-analysis of genome-wide association studies has identified six biological pathways that may be involved in the genetic predisposition to develop bipolar disorder. [More]
Bayer’s Adempas now available in the UK to treat patients with CTEPH

Bayer’s Adempas now available in the UK to treat patients with CTEPH

Adempas (riociguat) is available in the UK today as the first drug treatment for CTEPH, to treat adult patients with WHO Functional Class (FC) II to III with inoperable or persistent disease to improve exercise capacity. [More]
Advertisement
Advertisement